News Category
BioVersys and GSK will present Phase 2 data on alpibectir-ethionamide for drug-sensitive pulmonary tuberculosis at The Union World Conference on Lung ...
NanoViricides is advancing its broad-spectrum antiviral drug NV-387 into Phase II clinical trials for measles, addressing an unmet medical need as mea...
The American Heart Association awarded MedRhythms and Vascudyne top honors at its Health Tech Competition, highlighting technologies that could transf...
Tonix Pharmaceuticals reported a sharp jump in third-quarter revenue driven by strong TONMYA sales, while advancing its clinical pipeline and extendin...
Lifordi Immunotherapeutics' Phase 1 data for LFD-200, a subcutaneous glucocorticoid antibody-drug conjugate, demonstrate safety and anti-inflammatory ...
A landmark trial shows left bundle branch pacing reduces death, heart failure hospitalization, and pacing-induced cardiomyopathy compared to standard ...
New research shows that intensive blood pressure control in stroke survivors reduces the risk of major cardiovascular events by 21%, highlighting the ...
Adding spironolactone to post-stroke care significantly lowers blood pressure and helps more survivors reach recommended targets, potentially reducing...
The ZEUS trial found that ziltivekimab, an interleukin-6 inhibitor, did not reduce major cardiovascular events despite lowering inflammation markers i...
A new review identifies EGFR signaling as a central driver of mucus hypersecretion in asthma, COPD, and other lung diseases, and evaluates emerging th...
A new global analysis shows pediatric stroke deaths and disability have dropped sharply since 1990, yet rising adolescent incidence and persistent hem...
Quantum BioPharma (NASDAQ: QNTM) is advancing a diversified strategy that combines clinical drug development, consumer wellness, and royalty-based par...
Annovis Bio's proposed public offering aims to raise capital to advance its lead drug candidate buntanetap through Phase 3 trials for Alzheimer's and ...
Tonix Pharmaceuticals' upcoming presentation at the Guggenheim Healthcare Innovation Conference provides a platform to highlight its commercial-stage ...
Quantum BioPharma is advancing a diversified strategy that combines clinical drug development, consumer wellness, and royalty-based partnerships to ad...
Quantum BioPharma's unbuzzd supplement drink, designed to support alcohol metabolism, has received early praise from Men's Fitness following a small p...
Quantum BioPharma’s unbuzzd supplement, designed to support alcohol metabolism, has drawn scrutiny from Men’s Fitness after a placebo-controlled trial...
Okogen has dosed the first patient in its Phase 1/2 EMERALD Trial of Treyegen, a single ophthalmic therapy for acute infectious conjunctivitis, markin...
A preliminary study shows that non-specialist health workers using AI guidance can perform quality heart scans in mobile units, potentially improving ...
New preliminary research shows that extreme heat significantly increases out-of-hospital cardiac arrest ICU admissions, particularly among women and o...
Catherine Cifuentes-Rojas released a free checklist to help biotherapeutics teams make evidence-based go/no-go decisions, aiming to protect capital an...
Quantum BioPharma's agreement with Thermo Fisher Scientific's clinical research business marks a key step toward launching a Phase 2 trial for Lucid-M...
Annovis Bio's CEO will present at two November industry conferences, offering investors and partners a closer look at the company's Phase 3 clinical p...
NanoViricides' Phase IIA trial of NV-387 Oral Gummies for Ebola Bundibugyo progresses, with Phase IIB anticipated, offering a potential oral treatment...
A mutated flu strain is driving an earlier-than-expected outbreak on the West Coast, prompting urgent vaccination calls and highlighting the need for ...
Tonix Pharmaceuticals' TONMYA demonstrated statistically significant and sustained improvements in pain, symptom severity, and physical function in tw...
Tonix Pharmaceuticals will report third-quarter 2026 financial results on November 9, 2026, providing investors with an update on its commercial launc...
Annovis Bio will present three sessions at the 2026 CTAD conference on its Alzheimer's drug buntanetap, including Phase 3 design and AI-based blood-br...
NeuroThera Labs has completed manufacturing and obtained European QP batch release for its SCI-110 investigational drug, enabling shipment to trial si...
BioVersys announced peer-reviewed publications of Phase 1 data showing its antibiotic BV100 achieves high lung concentrations and has a milder drug-in...
Quantum BioPharma's Unbuzzd formulation showed a 40.7% greater reduction in estimated blood alcohol among rapid responders compared to placebo, but th...
NanoViricides announced positive juvenile animal safety results for its broad-spectrum antiviral NV-387, supporting potential pediatric clinical trial...
Quantum BioPharma's Unbuzzd alcohol recovery formulation gained mainstream attention through a Men's Fitness article, but the study's small sample siz...
Tonix Pharmaceuticals will present poster data on TONMYA's effects on fibromyalgia symptoms and physical function at the 2026 IASP World Congress on P...
Measles infections cause long-term immune vulnerabilities that make survivors susceptible to other diseases, highlighting the urgent need for increase...
Tonix Pharmaceuticals will present its TNX-801 vaccine platform at the World Vaccine Congress Europe, highlighting its potential to address mpox and o...
OrthodontiCell has secured sufficient capital to complete the testing required for its application to launch a Phase II pivotal study in the U.S., adv...
hyperCORE International has elected new officers to lead its strategic scaling platform, reinforcing its dual mission of accelerating growth for indep...
Quantum BioPharma's FDA clearance to begin Phase 2 testing of Lucid-MS, a non-immunomodulatory MS drug, could offer a new treatment paradigm for multi...
The American Heart Association's selection of five health technology finalists for its 2026 competition highlights a strategic push to overcome adopti...
NanoViricides reports progress in its Phase IIA Ebola treatment trial of NV-387 Oral Gummies, potentially paving the way for a Phase IIB study and off...
Nutriband's $1.75 million warrant exercise proceeds will fund the clinical development and FDA submission for its abuse-deterrent fentanyl patch, pote...
Leksum LLC has signed an agreement with the Medical University of Vienna to prepare for Phase I/II clinical trials of LK-ICU, a biologic candidate tha...
The American Heart Association has expanded its education portfolio to help clinicians implement the new cardiovascular-kidney-metabolic syndrome guid...
Newron Pharmaceuticals has received written FDA feedback on the clinical hold at U.S. study centers for its Phase 3 ENIGMA-TRS 2 trial of evenamide, w...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to implement a Phase 2 trial of Luc...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business to launch a Phase 2 trial for Lucid-MS marks a significant step toward a...
Quantum BioPharma's agreement with Thermo Fisher Scientific to conduct the Phase 2 trial of Lucid-MS marks a critical step toward developing a first-i...
